Seattle Genetics Inc. (SGEN)

55.35
NASDAQ : Health Technology
Prev Close 53.78
Day Low/High 53.44 / 55.45
52 Wk Low/High 45.31 / 71.31
Avg Volume 1.15M
Exchange NASDAQ
Shares Outstanding 157.95M
Market Cap 8.55B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics Commences Tender Offer For Cascadian Therapeutics, Inc.

Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that its wholly-owned subsidiary, Valley Acquisition Sub, Inc.

Seattle Genetics Reports Fourth Quarter And Year 2017 Financial Results

Seattle Genetics Reports Fourth Quarter And Year 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ:SGEN) today reported financial results for the fourth quarter and year ended December 31, 2017.

Seattle Genetics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

Seattle Genetics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,730,769 shares of Seattle...

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

Seattle Genetics Announces Pricing Of Public Offering Of Common Stock

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the pricing of an underwritten public offering of 11,538,461 shares of its common stock at a price to the public of $52.

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics Announces Proposed Public Offering Of Common Stock

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has commenced an underwritten public offering of $550.

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics To Acquire Cascadian Therapeutics, Adding Late-Stage Breast Cancer Program To Its Oncology Pipeline

Seattle Genetics, Inc. (Nasdaq:SGEN) and Cascadian Therapeutics, Inc.

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval For CD30-Positive Cutaneous T-Cell Lymphoma After At Least One Prior Systemic Therapy

Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Receives European Commission Approval For CD30-Positive Cutaneous T-Cell Lymphoma After At Least One Prior Systemic Therapy

Seattle Genetics, Inc. (Nasdaq: SGEN) reported today that its collaborator, Takeda Pharmaceutical Company Limited, announced that the European Commission has extended the current conditional marketing authorization...

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2017 Financial Results On February 6, 2018

Seattle Genetics To Host Conference Call And Webcast Discussion Of Fourth Quarter And Year 2017 Financial Results On February 6, 2018

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it will report its fourth quarter and year 2017 financial results on Tuesday, February 6, 2018 after the close of financial markets.

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Deere & Co., Analog Devices, Mercadolibre: 'Mad Money' Lightning Round

Jim Cramer is bullish on Deere & Co., Analog Devices, Mercadolibre, Teradyne, AbbVie, Antero Midstream Partners.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Seattle Genetics Highlights Leadership In Expanding Field Of Antibody-Drug Conjugates (ADCs) At The 36th Annual J.P. Morgan Healthcare Conference

Seattle Genetics Highlights Leadership In Expanding Field Of Antibody-Drug Conjugates (ADCs) At The 36th Annual J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ: SGEN) highlighted today the progress of its pipeline of antibody-drug conjugates (ADCs) at the 36 th Annual J.

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics To Present At The J.P. Morgan Healthcare Conference

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that Clay B.

Seattle Genetics And Bristol-Myers Squibb Highlight Interim Results From Phase 1/2 Study Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Relapsed Or Refractory Hodgkin Lymphoma

Seattle Genetics And Bristol-Myers Squibb Highlight Interim Results From Phase 1/2 Study Evaluating The Combination Of ADCETRIS® (Brentuximab Vedotin) And Opdivo® (Nivolumab) In Relapsed Or Refractory Hodgkin Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS (brentuximab...

Seattle Genetics Highlights Five-Year Survival Results From Phase 1 Trial Of ADCETRIS® (Brentuximab Vedotin) In Frontline Mature T-Cell Lymphoma At ASH Annual Meeting

Seattle Genetics Highlights Five-Year Survival Results From Phase 1 Trial Of ADCETRIS® (Brentuximab Vedotin) In Frontline Mature T-Cell Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted final five-year survival results from a phase 1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in mature T-cell lymphoma (MTCL) at the 59 th American...

Seattle Genetics Highlights Updated Analyses From Phase 3 ALCANZA Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In CD30-Expressing Cutaneous T-Cell Lymphoma At ASH Annual Meeting

Seattle Genetics Highlights Updated Analyses From Phase 3 ALCANZA Clinical Trial Of ADCETRIS® (Brentuximab Vedotin) In CD30-Expressing Cutaneous T-Cell Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN) today highlighted updated results from the phase 3 ALCANZA clinical trial evaluating ADCETRIS (brentuximab vedotin) in CD30-expressing cutaneous T-cell lymphoma (CTCL) at the 59 th...

Seattle Genetics Presents Updated Phase 1 Data For Ladiratuzumab Vedotin (SGN-LIV1A) In Patients With Triple Negative Breast Cancer At 2017 San Antonio Breast Cancer Symposium

Seattle Genetics Presents Updated Phase 1 Data For Ladiratuzumab Vedotin (SGN-LIV1A) In Patients With Triple Negative Breast Cancer At 2017 San Antonio Breast Cancer Symposium

Seattle Genetics, Inc. (NASDAQ: SGEN) today announced updated data from an ongoing phase 1 clinical trial evaluating ladiratuzumab vedotin in patients with metastatic triple negative breast cancer (TNBC) at the 2017...

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics To Webcast Investor And Analyst Event At American Society Of Hematology Annual Meeting

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the company will webcast an investor and analyst event on Monday, December 11, 2017 during the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta,...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AINV, AMOT, ANIP, EXFO, EXPR, INBK, LIND, LNN, LTM, MJCO, MYRG, SGEN, WEYS Downgrades: BAM, ESRT, IAG, PGRE, RRTS, SSRM Initiations: RARE Read on to get TheStreet Quant Ratings' detailed report:

Www.astellas.com/en

Www.astellas.com/en

Seattle Genetics, Inc. (NASDAQ: SGEN) and Astellas Pharma Inc.

Seattle Genetics Submits Supplemental Biologics License Application To FDA For ADCETRIS® (Brentuximab Vedotin) In Frontline Advanced Hodgkin Lymphoma

Seattle Genetics Submits Supplemental Biologics License Application To FDA For ADCETRIS® (Brentuximab Vedotin) In Frontline Advanced Hodgkin Lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.

Seattle Genetics To Present Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program At ASH 2017

Seattle Genetics To Present Data From Broad ADCETRIS® (Brentuximab Vedotin) Development Program At ASH 2017

Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that 18 abstracts featuring data from the broad ADCETRIS (brentuximab vedotin) development program have been accepted for presentation, including a plenary...

Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers

Versartis Drops on Q3 Numbers, Hires Adviser -- Biotech Movers

The Menlo Park, Calif.-based firm on Thursday reported third-quarter results and said it has hired Cowen to help with evaluating potential transactions.

Seattle Genetics Reports Third Quarter 2017 Financial Results

Seattle Genetics Reports Third Quarter 2017 Financial Results

Seattle Genetics, Inc. (NASDAQ: SGEN) today reported financial results for the third quarter and nine months ended September 30, 2017.

Catch of the Day: Cramer's 'Mad Money' Recap (Wednesday 10/11/17)

Catch of the Day: Cramer's 'Mad Money' Recap (Wednesday 10/11/17)

This market is unique in the way fresh leadership emerges each day to take it higher, Jim Cramer says.

TheStreet Quant Rating: C- (Hold)